II期临床-话题@MedSci

#II期临床#

478篇内容 | 2553人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524927, encodeId=c0ea152492e96, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, objectType=article, longId=207295, objectId=aa7320e295db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7320e295db, replyNumber=0, likeNumber=61, createdTime=2021-02-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7320e295db, moduleTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7320e295db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524926, encodeId=089a152492682, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, objectType=article, longId=207256, objectId=1d0f20e25662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0f20e25662, replyNumber=0, likeNumber=20, createdTime=2021-02-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0f20e25662, moduleTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0f20e25662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524925, encodeId=c8b915249255c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, objectType=article, longId=207001, objectId=7c4620e00147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4620e00147, replyNumber=0, likeNumber=71, createdTime=2021-02-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4620e00147, moduleTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4620e00147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524924, encodeId=49f31524924bb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：III期临床证实mRNA-1273疫苗有效率达94.1%, objectType=article, longId=206787, objectId=a50f206e879d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a50f206e879d, replyNumber=0, likeNumber=64, createdTime=2021-02-06, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a50f206e879d, moduleTitle=NEJM：III期临床证实mRNA-1273疫苗有效率达94.1%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a50f206e879d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524923, encodeId=3df315249233a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, objectType=article, longId=206565, objectId=0ffe20656522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ffe20656522, replyNumber=0, likeNumber=147, createdTime=2021-02-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ffe20656522, moduleTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ffe20656522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524922, encodeId=e32b1524922ad, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Brilacidin治疗COVID-19的II期临床试验，计划于下周开始, objectType=article, longId=206528, objectId=f96e206528c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96e206528c2, replyNumber=0, likeNumber=79, createdTime=2021-02-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96e206528c2, moduleTitle=Brilacidin治疗COVID-19的II期临床试验，计划于下周开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96e206528c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524921, encodeId=14471524921e8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lenzilumab治疗COVID-19住院患者，即将开展III期临床, objectType=article, longId=206522, objectId=76e2206522a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76e2206522a7, replyNumber=0, likeNumber=63, createdTime=2021-02-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76e2206522a7, moduleTitle=Lenzilumab治疗COVID-19住院患者，即将开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76e2206522a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524920, encodeId=854315249204c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, objectType=article, longId=206516, objectId=fdf420651685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf420651685, replyNumber=0, likeNumber=55, createdTime=2021-02-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf420651685, moduleTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdf420651685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524919, encodeId=082e15249192c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=脱发新疗法！FOL-005的II期临床研究已接近尾声, objectType=article, longId=206428, objectId=acf720642822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acf720642822, replyNumber=0, likeNumber=86, createdTime=2021-01-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acf720642822, moduleTitle=脱发新疗法！FOL-005的II期临床研究已接近尾声, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acf720642822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524918, encodeId=12341524918bd, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功, objectType=article, longId=205725, objectId=edf1205e25a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf1205e25a9, replyNumber=0, likeNumber=77, createdTime=2021-01-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf1205e25a9, moduleTitle=NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf1205e25a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524917, encodeId=ab43152491e51, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, objectType=article, longId=205711, objectId=ced5205e1160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced5205e1160, replyNumber=0, likeNumber=70, createdTime=2021-01-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced5205e1160, moduleTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced5205e1160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524916, encodeId=016a152491652, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功, objectType=article, longId=205638, objectId=cd2320563849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2320563849, replyNumber=0, likeNumber=49, createdTime=2021-01-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2320563849, moduleTitle=Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2320563849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524915, encodeId=666f15249153a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, objectType=article, longId=205630, objectId=ad3c205630c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad3c205630c9, replyNumber=0, likeNumber=41, createdTime=2021-01-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad3c205630c9, moduleTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad3c205630c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524914, encodeId=49941524914f2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=国药新冠疫苗国内上市申请获受理，III期临床仍在继续, objectType=article, longId=205619, objectId=442220561905, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442220561905, replyNumber=0, likeNumber=101, createdTime=2021-01-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442220561905, moduleTitle=国药新冠疫苗国内上市申请获受理，III期临床仍在继续, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442220561905)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524913, encodeId=9d9015249132b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Falkieri治疗双相抑郁症：II期临床取得了阳性结果, objectType=article, longId=205566, objectId=fd1d2055667a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd1d2055667a, replyNumber=0, likeNumber=98, createdTime=2021-01-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd1d2055667a, moduleTitle=Falkieri治疗双相抑郁症：II期临床取得了阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd1d2055667a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524912, encodeId=77f4152491263, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=LX9211治疗神经性疼痛，即将开展II期临床研究, objectType=article, longId=205264, objectId=56012052643d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56012052643d, replyNumber=0, likeNumber=101, createdTime=2021-01-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56012052643d, moduleTitle=LX9211治疗神经性疼痛，即将开展II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56012052643d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524911, encodeId=6d5715249114d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, objectType=article, longId=205036, objectId=8f5c20503649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5c20503649, replyNumber=0, likeNumber=78, createdTime=2021-01-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5c20503649, moduleTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f5c20503649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524910, encodeId=6a2f1524910fa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=国药中生发布新冠灭活疫苗III期临床期中分析结果，保护效力79.34%【附点评】, objectType=article, longId=205020, objectId=fbac2050204d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbac2050204d, replyNumber=0, likeNumber=68, createdTime=2021-01-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbac2050204d, moduleTitle=国药中生发布新冠灭活疫苗III期临床期中分析结果，保护效力79.34%【附点评】, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbac2050204d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524909, encodeId=4355152490936, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究, objectType=article, longId=204977, objectId=9fff2049e7bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fff2049e7bf, replyNumber=0, likeNumber=0, createdTime=2020-12-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fff2049e7bf, moduleTitle=新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fff2049e7bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524908, encodeId=d25f152490857, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=51, createdTime=2020-12-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验

2021-02-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验

2021-02-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床

2021-02-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：III期临床证实mRNA-1273疫苗有效率达94.1%

2021-02-06

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验

2021-02-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Brilacidin治疗COVID-19的II期临床试验，计划于下周开始

2021-02-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lenzilumab治疗COVID-19住院患者，即将开展III期临床

2021-02-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募

2021-02-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

脱发新疗法！FOL-005的II期临床研究已接近尾声

2021-01-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功

2021-01-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点

2021-01-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功

2021-01-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验

2021-01-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

国药新冠疫苗国内上市申请获受理，III期临床仍在继续

2021-01-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Falkieri治疗双相抑郁症：II期临床取得了阳性结果

2021-01-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

LX9211治疗神经性疼痛，即将开展II期临床研究

2021-01-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验

2021-01-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

国药中生发布新冠灭活疫苗III期临床期中分析结果，保护效力79.34%【附点评】

2021-01-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究

2020-12-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2020-12-30

科室
- - 订阅+
  - 更多科室
工具
服务